Past Coverage of the Duke Scandal

The Cancer Letter’s Past Coverage of The Duke Scandal

	Oct. 2, 2009 A Biostatistics Paper Alleges Potential Harm to Patients In Two Duke Clinical Studies
	Oct. 9, 2009 Duke University Suspends Two Clinical Trials After Journal Paper Questions Assay Validity
	Oct. 23, 2009 Duke Halts Third Trial; Coauthor Disputes Claim That Data Validation Was Blinded. Moffitt Ends Pilot Study Based On Duke Test, Says Action Unrelated
	Jan. 29, 2010 Duke Plans To Restart Three Trials Using Tumor Microarray Analysis
	May 14, 2010 NCI Raises New Questions About Duke Genomics Research, Cuts Assay From Trial The Cancer Letter Obtains “Confidential” Documents From Duke IRB Investigation Report Doesn’t Quell Concerns About Duke Genomics Research, Biostatisticians Say
	July 16, 2010 Prominent Duke Scientist Claimed Prizes He Didn’t Win, Including Rhodes Scholarship.
	July 23, 2010 By Defending Potti, Duke Officials Become Target Of Charges Of Institutional Failure Duke Officials Decline To Provide Details Of Probe. Biostatisticians Write To Varmus Asking NCI To Investigate The Lancet Oncology Issues “Expression Of Concern” Over Paper Duke Insiders Allege Intimidation By Administration
	July 30, 2010 Varmus, Duke Ask IOM To Investigate Potti’s Scientific Work, Clinical Trials Michigan Scientist David Beer Sought Retraction Of Potti’s NEJM Paper Over Misuse Of His Data Potti Claimed Rhodes Credential in Bio Submitted for DOD Funding Duke Vice Dean Cuffe Promises Complete, Independent Probe Of Work By Potti, Nevins.
	Oct. 1, 2010 An Impromptu Group Proposes Standards For Publication Of Genomics Research IOM To Form Committee To Investigate Duke Genomics Research
	Oct. 22, 2010 IOM Review Of Duke Genomics Trials To Focus On Validation, Scientific Criteria
	Oct. 29, 2010 Nevins Retracts Key Paper By Duke Group, Raising Question Of Harm To Patients Retraction Based On Data Given To Duke Last November, But Apparently Disregarded
	Nov. 5, 2010 Duke Retraction May Alter IOM Investigation; Review Panel Membership Announced
	Nov. 19, 2010 JCO Retracts Key Duke Genomics Paper; Duke Shuts Down Three Phase II Trials; Anil Potti Resigns From Duke University
	Jan. 7, 2011 IOM Committee Will Probe Duke Scandal Together With Other “Omics” Case Studies NCI Releases 550 Pages of Internal Documents Related to Duke Scandal
	Jan. 14, 2011 Duke Deans Acknowledge Withholding Key Document From Outside Reviewers
	Jan. 28, 2011 FDA Auditors Spend Two Weeks at Duke, Nevins Loses Position in Reorganization
	Feb. 4, 2011 The Lancet Oncology retracts Potti paper, NEJM doesn’t
	March 4, 2011 The Duke Scandal: NEJM retracts Potti paper
	April 1, 2011 Nevins: Duke Administration Did a “Very Good Job” of Handling the Crisis
	April 15, 2011 Guest Editorial: Anil Potti hires “online reputation managers” as journals retract his biomarker research
	June 3, 2011 Anil Potti Joins Myrtle Beach Private Practice
	July 22, 2011 A Year at NCI: Harold Varmus Reflects on Provocative Questions, the Duke Scandal, Financial Disaster and Grant Review
	July 29, 2011 Part II of Q&A With NCI Director Harold Varmus
	Sept. 9, 2011 Duke Researchers Retract Paper from Blood; Dozens of Retractions of Potti’s Work Expected Clinical Trial Participants Sue Duke University, Potti, Nevins and Others for Causing Harm
	Sept. 16, 2011 Another Potti Paper Retracted
	Dec. 9, 2011 Anil Potti Reprimanded by North Carolina Licensure Board Duke University Settles 11 Medical Malpractice Cases Related to Potti’s trials Excerpts From Potti’s Application to Practice Medicine In South Carolina
	Dec. 16, 2011 Anil Potti Explains: “Coming from India, I Did Not Know This Was Not The Real Rhodes Scholarship”
	Jan. 27, 2012 FDA Didn’t Punish Duke for Failing To Seek Proper Regulatory Clearance for Three Trials News Analysis by Keith Baggerly: Duke Trials Went On Despite FDA Statements
	Feb. 10, 2012 60 Minutes to air segment on the “Deception at Duke”
	Feb. 17, 2012 Nevins Reverses Position, Claims Potti Manipulated Data For Basis of Clinical Trials
	Feb. 24, 2012 South Carolina Clinic and Anil Potti Part Ways
	March 23, 2012 IOM Omics Committee Offers Blueprint to Prevent Other Duke-Style Disasters
	Feb. 8, 2013 NCI Unveils Checklist for Omics Studies
	Oct. 18, 2013 NCI Sets Rules For Omics Studies Exit Joseph Nevins: Duke’s Genomics Luminary Quietly Leaves
	Jan. 9, 2015 Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
	Jan. 16, 2015 Duke Scientist: I Hope NCI Doesn’t Get Original Data
	Jan. 23, 2015 Duke’s Legal Stance: We Did No Harm
	Jan. 23, 2015 Misconduct Expert Dissects Duke Scandal

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

News Analysis

Dana-Farber’s bold split from the Brigham is a culmination of Boston oncology’s complicated history

It’s a divorce everyone has an opinion on.

December 08, 2023

Vol.49 No.45

By Jacquelyn Cobb

As Bertagnolli steps in, NIH and FDA reenvision clinical trials and evidence generation

NIH and FDA envision transforming the way clinical trials are done across the biomedical research enterprise.

December 08, 2023

Vol.49 No.45

By Matthew Bin Han Ong

Guest Editorial

New leadership, vision for the Worldwide Innovative Network Consortium in precision oncology

From the time of its inception, the Worldwide Innovative Network (WIN) Consortium in precision cancer medicine has had a bold mission to significantly improve survival of patients with cancer across the world through international collaboration.

Turning the page: Projections for cancer care in the coming year

As 2024 approaches, it’s anyone’s guess whether an already complex health care ecosystem gets to turn the corner on the mixed legacies of 2023—including record high prices on new blockbuster medications coupled with drug shortages on existing generics, persistent staff shortages and battered hospital margins, and a continued emphasis on value-based care programs by insurers.

The field of population epigenetics is failing on rigor and reproducibility

To the editor, I was not booed off the stage. Rather, the response was incredibly enthusiastic. After my session people lined up for over 45 minutes to talk to me. Many thanked me for publicizing this issue, indicating that the problems with the Illumina platform have been apparent to many, but no one else was...

December 08, 2023

Vol.49 No.45

In the Archives

Videos commemorate 50 years of NCI SEER registries

NCI’s Surveillance, Epidemiology, and End Results Program in the Division of Cancer Control and Population Sciences at NCI is marking 50 years of cancer surveillance.

December 08, 2023

Vol.49 No.45

Past Coverage of the Duke Scandal

The Cancer Letter’s Past Coverage of The Duke Scandal

YOU MAY BE INTERESTED IN

Dana-Farber’s bold split from the Brigham is a culmination of Boston oncology’s complicated history

As Bertagnolli steps in, NIH and FDA reenvision clinical trials and evidence generation

New leadership, vision for the Worldwide Innovative Network Consortium in precision oncology

Turning the page: Projections for cancer care in the coming year

The field of population epigenetics is failing on rigor and reproducibility

Videos commemorate 50 years of NCI SEER registries

Renew today!

Subscriber content

Login